Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines

Zhiwei Li, Zhiqian Ma, Yang Li, Sheng Gao, Shuqi Xiao

College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, China

ARTICLE INFO

Keywords: Porcine epidemic diarrhea virus Vaccine Virulence Genetics

ABSTRACT

Porcine epidemic diarrhea virus (PEDV) causes an emerging and re-emerging coronavirus disease characterized by vomiting, acute diarrhea, dehydration, and up to 100% mortality in neonatal suckling piglets, leading to huge economic losses in the global swine industry. Vaccination remains the most promising and effective way to prevent and control PEDV. However, effective vaccines for PEDV are still under development. Understanding the genomic structure and function of PEDV and the influence of the viral components on innate immunity is essential for developing effective vaccines. In the current review, we systematically describe the recent developments in vaccine against PEDV and the roles of structural proteins, non-structural proteins and accessory proteins of PEDV in affecting viral virulence and regulating innate immunity, which will provide insight into the rational design of effective and safe vaccines for PEDV or other coronaviruses.

1. Introduction

Since 2010, highly pathogenic variant porcine epidemic diarrhea virus (PEDV) strains have gradually swept the swine industry worldwide and brought substantial economic losses. Such a huge hazard of the virus is inseparable from its strong transmissibility. Generally, the main transmission route of PEDV is fecal-oral, but airborne transmission via the fecal-nasal route may play a significant role in pig-to-pig and farm-to-farm spread [1]. PEDV mainly infects the porcine intestinal epithelial cells. Then, PEDV colonizing the intestines results in atrophy, necrosis, and shedding of intestinal villi, which affected the absorption of nutrients, leading to vomiting, diarrhea, weight loss, anorexia, and depression [2,3]. When PEDV is excreted into the environment with feces, the contaminated feces may result in a mass epidemic. Obtaining sufficient maternal antibody from thecolostrum and milk remains the most promising and effective strategy to protect neonatal suckling piglets against PEDV [4]. Unfortunately, due to the continued mutation of the PEDV genome [5] and the low efficacy to induce mucosal immunity, no effective vaccine has been released yet. Therefore, in-depth research on this disease as well as its pathogenesis and the rapid development of effective vaccines based on the epidemic strains are urgently needed.

2. PEDV genome structure and functions

PEDV is an enveloped virus with a single-stranded, positive-sense RNA genome that belongs to the order Nidovirales, family Coronaviridae and genus Alphacoronavirus. The genome of PEDV is approximately 28 kb and arranged in the order of the 5′ untranslated region (5′ UTR), open reading frame 1 a/b (orf1ab), spike (S) protein, accessory proteins (ORF3), envelope (E) protein, membrane (M) protein, nucleocapsid (N) protein, 3′ UTR, and the poly (A) tail (Fig. 1). Pp1ab, encoded by the partially overlapping 5′-terminal of PEDV genome, can be cleaved into 16 non-structural proteins (nsp) named nsp1-16 [6]. Among these proteins, the S protein is a type I glycoprotein and a receptor-binding protein that plays an important role in virial entry, virus-host interactions and determining immunogenicity evaluation. The S protein consists of S1 and S2 subunits. The amino terminal of S1 subunit (1–18 aa) is the N-terminal signal peptide, 19–233 aa is the sialic acid binding region, and 499–638 aa is the core neutralizing epitope (COE) region. The N-terminal signal peptide, 19–233 aa is the sialic acid binding region, and 499–638 aa is the core neutralizing epitope (COE) region. The S2 subunit contains a fusion peptide (FP, 891–908 aa), two heptad repeat regions HR1 (978–1117 aa) and HR2 (1274–1313 aa), a transmembrane region (1328–1350 aa) and a cytoplasmic domain (CP, 1351–1386 aa) in C-terminal [7,8]. Each structural and non-structural protein play an important role in the viral replication, transcription and translation as well as virus-host cell interactions. Table 1 summarizes the biological
roles of PEDV proteins.

2.1. Non-structure proteins

The Nsp1 protein, a unique structure of alphacoronaviruses and betacoronaviruses, is located at the N-terminus of pp1ab [9]. Nsp1 is considered to be a virulence gene of coronavirus, which widely inhibits host genes’ expression to suppress or evade the innate immune response and facilitate viral replication [10]. The nsp1 of severe acute respiratory syndrome coronavirus (SARS-CoV) significantly inhibited host gene expression, including that of type I interferon (IFN), by binding to the ribosome, which led to endonucleolytic cleavage and subsequently promoted host endogenous mRNA degradation in vitro [11–13]. Moreover, abolishing the IFN suppression activity reduced viral virulence in vivo, the deletion of the regions ∆LLRKNNGK (121–129 aa) and ∆EDYEQWNWTKH (154–164 aa) in nsp1 led to SARS-CoV attenuation in mice. MHV-nsp1Δ99(829–927 nt) and MHV-nsp1Δ27 (LRKxGxKG) were also strongly attenuated but maintained the protection against challenge with the WT MHV virus in vivo [14–18]. IRF1 mediated type III IFN production via interactions with the IFNα/β receptor in the nucleus [19,20], and the increase in peroxisome abundance was correlated with an increase in IFNα mRNA production [21]. NF-κB triggers IFN-β expression by binding to the respective positive regulatory domain (PRD)II element of type I IFNs when NF-κB was released from the NF-κB/IκBα complex and transported to the nucleus after the IκBα was phosphorylated and degraded by the IκB kinase complex [22–24]. IRF3 turned on the expression of type I IFN via forming an IFNα/βR complex binding to the PRD I/III of the IFN promoter [25,26]. PEDV nsp1 inhibited IFN production by blocking the nuclear translocation of IRF1, reducing the number of peroxisomes, and interfering with the phosphorylation and degradation of IκBα, which could prevent the activation of p65 and suppress the PRD II-mediated NF-κB activity in vitro [27,28]. The highly conserved residues of nsp1 were crucial for type III IFNs and IRF1 suppression activities. The amino acid mutant F44A abolished the suppression activities of nsp1 in vitro, and the PEDV strain containing nsp1 F44A mutation had higher levels of IFN-β, IFN-λ1 and ISG54 in LLC-PK1 cells and reduced the level of fecal virus shedding without significant pathological lesions in the jejunum and ileum in piglets. In addition, the degradation of CBF by nsp1 interrupted the assembly of IRF3 and CREB binding protein (CBP), resulting in the further suppression of IFN and proinflammatory cytokine [29,30]. Crystal structure showed that PEDV nsp1 consists of two α-helices and six β-strands, and six stranded β-barrel folds in the middle of two α-helices. Ribopurinomycylation and renilla luciferase reporter assays indicated that 67–71 aa, 78–85 aa, and 103–110 aa of the nsp1 create a stable positive charge.

![Fig. 1. (a) Schematic structure of the virion of PEDV. (b) Schematic diagram of the genome of PEDV. Structural proteins, including spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, as well as accessory proteins ORF3 and non-structural proteins derived from pp1ab, including nsp1-16, papain-like protease (PLpro, nsp3), 3C-like protease (3CLpro, nsp5), RNA-dependent RNA polymerase (RdRp, nsp12), 5′-to-3′ Helicase (HEL, nsp13), exoribonuclease (ExoN, nsp14), endoribonuclease (EndoU, nsp15), 2′-O-methytransferases (2′-O-MTase, nsp16). Spike protein, including signal peptide (SP, 1–18 aa), sialic acid-binding region (SIA, 19–233 aa), core neutralizing epitope (COE, 499–638 aa), fusion peptide (FP, 891–908 aa), heptad repeat domain (HR1, 978–1117 aa and HR2, 1274–1313 aa), transmembrane domain (TM, 1328–1350 aa), and cytoplasmic domain (CP, 1351–1386 aa).](image-url)
functional region that may help PEDV to inhibit host protein synthesis, including that of IFN [31,32]. Nevertheless, the specific mechanism of PEDV nsp1-mediated immunosuppression was entirely unclear and whether PEDV nsp1 inhibited host gene expression in a ribosome-dependent manner similar to that of SARS-CoV and SARS-CoV-2 needs further research [33].

Nsp3 encodes Papain-like protease (PLpro) present in various coronaviruses. The PLpro are responsible for the cleavage of the portion of the ORF1ab polyprotein encoded by the incoming RNA genome, which is essential for viral RNA synthesis [34]. The PLpro usually cleaves nsp1-4 and the cleavage sites can be summarized with LXGG or the similar motif in SARS-CoV and MHV [35–37]. Furthermore, PLpro strongly antagonizes the expression of IFN and interferon-stimulated genes (ISGs). The PLpro of SARS-CoV interacts with IRF3 and inhibits the phosphorylation and nuclear translocation of IRF3-3, thereby disrupting the activation of the type I IFN pathway through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-related gene 5 pathways [38]. The STING-MAVS-TBK1/IKK complexes could activate IRF3, which is subsequently transported to the nucleus and induces the expression of type I IFN genes by binding to the PRD(III-I) sequences and the phosphorylation of STING mediated by TBK1 is required for STING-mediated activation of IRF3 [26,28,39,40]. Moreover, dimerization of STING is also critical for self-activation and the ability to induce type I IFN [41]. PLpro encoded by NL63-CoV, SARS-CoV, and PEDV antagonized STING-mediated antiviral innate immunity by disrupting STING dimers and the deubiquitination of RIG-I and STING, and the catalytic mutants (C1729A, H1888A, D1901A) in PEDV nsp3 reduced the inhibition of IFN-β and PRD(III-I)4 promoter activity in vitro, which could be applied to the design of the PEDV attenuated vaccine [42,43]. Moreover, amino acids 590–1215 of TGEV nsp3 have been proven to evade the host immune system by NF-κB pathway [44], whether PEDV uses similar amino acids for immune evasion needs to be further studied.

Contrary to the effect of PEDV nsp3, PEDV nsp4 could upregulate the expression of IL-1α, IL-1β, TNF-α, CCL2, CCL5 and CXCL8 by activating the NF-κB promoter and silencing these cytokine genes inhibited viral replication in vitro [45].

3C-like protease (3Cpro), encoded by the gene for nsp5, processes the viral nsp4–nsp16 part of pp1ab at 11 cleavage sites, which could be summarized with the P2–P1′ consensus motif X-(L/I/V/F/M)-Q/i(S/A/G) and X is any amino acid and i represents the cleavage in SARS-CoV and other coronaviruses [37,46–50]. 3Cpro plays a pivotal role in coronaviruses replication, thus serving as an appealing antiviral drug target. Inhibition of PEDV nsp5 effectively inhibited the replication of PEDV, for instance, the broad-spectrum inhibitor GC376 reduced viral replication via binding the catalytic pocket of PEDV 3Cpro [51,52]. In the process of interaction with the host, NEMO (IKKγ) acting as a signaling adaptor of the RIG-I/MDAS pathway plays an important role in the phosphorylation of NF-κB and IRF3, which directly activate promoters of type I IFNs [53,54]. PEDV nsp5 cleaved NEMO at position 231 (Q231), which impaired the ability of NEMO to induce IFN production in vitro [55]. The functional coronavirus 3Cpro is dimeric. Each PEDV monomer contains three domains: domain I, domain II, and domain III. Domain I and domain II both exhibit an antiparallel β-barrel structure and domain III consists of five α helices [56]. The substrate catalytic domains of α- and β-coronavirus 3Cpro have two highly conserved residues known as His41 and Cys144 [57–60]. His41 and Cys144 mutating into Ala (H41A/C144A) eliminated the catalytic activity and IFN-β inhibitory capacity of PEDV nsp5 in PK-15 and HEK-293T cells [30]. The antagonistic effect of nsp5 on IFN suggested that it may be related to viral virulence. Besides, the nsp5 T26L/D65G MHV exhibited reduced enzymatic activity and was highly attenuated in IFNAR−/− mice [61]. Whether the PEDV strain with the H41A/C144A in nsp5 exhibits lower 3Cpro activity and reduced viral virulence needs to be further verified by reverse genetics.

Coronavirus nsp7–10 are essential regulatory subunits that are critical for coronavirus replication. The N-terminal region of SARS-CoV nsp8 possessed primase activity and was able to polymerize short RNA oligonucleotides utilized by the primer-dependent nsp12 RdRp during RNA synthesis [62]. The SARS-CoV hexadecameric nsp7–nsp8 supercomplex containing eight copies of nsp8 and eight copies of nsp7 [63] and the feline coronavirus (FCoV) Nsp7-Nsp8 heterotrimer both exhibited noncanonical RdRp activity [64]. The SARS-CoV nsp7-nsp8 supercomplex has a hollow cylindrical structure with different charges distributed on the surface and inside of the cylinder, which ensures that the phosphate backbone of nucleic acids can pass through the channel without electrostatic repulsions. In addition, an average internal diameter of approximately 30 Å could suitably hold the nascent and template strands together to facilitate efficient replication and transcription [65].

Interactions of nsp12 with nsp7 and nsp8 co-factors were crucial to the processivity to the RNA-synthesizing activity of nsp12 and a few mutations of nsp7 and nsp8 residues affected SARS-CoV replication by reducing nsp12 RNA polymerase activity [65,66]. PEDV nsp7 was found to inhibit the IFN-β and IRF3 promoter activities in HeLa cells [67]. Moreover, PEDV nsp8 was shown to suppress type III IFN activities by reduced IFR1 promoter activities in vitro. This fact suggested that nsp7 and nsp8 could be factors, though the specific mechanism of innate immunosuppression remains largely unknown. PEDV nsp9, containing seven antiparallel β-strands and one α-helix, is also critical for viral replication. Nsp9–RNA interactions may stabilize nascent viral RNAs during viral replication or transcription. The dimerization of PEDV nsp9 and its positively charged surface further enhanced the interaction between nsp9 and RNA [37,68–70]. SARS-CoV and MHV nsp10 are involved in viral replication via regulating the nsp14 ExoN and nsp16 2′-OmTase activities as well as the processing of the nsp4–nsp11 region [71–73]. Nsp13 of 229E-CoV and SARS-CoV possessing both helicases and NTPase activity, which could unwind either DNA or RNA in the 5′-to-3′ direction and utilize all four natural ribonucleotides and nucleotides as substrate, also plays an essential role in viral replication [74–77]. However, there is no direct evidence for the roles of nsp10 and nsp13 in PEDV replication.

CoV nsp14 possesses 3′-to-5′ exoribonuclease (ExoN) activity crucial for CoV RNA genome replication fidelity [78] and N7-methyltransferase (N7-MTase) activity involved in RNA cap formation that is also critical for viral transcribing and translation [79]. Abolishing the N7-MTase activity was lethal to PEDV, but retaining 25% of N7-MTase activity by mutating a single amino acid D350A in nsp14 was viable. In addition, this mutant induced significantly higher expression of both type I and III IFN. These results demonstrated that PEDV nsp14 N7-MTase activity efficiently modulates viral replication, gene expression, and innate immune responses in IPEC-DQ cells [80]. Recombinant rMHV encoding a G332A substitution in the N7-MTase region in nsp14 also displayed delayed replication kinetics and decreased peak titers but higher expression of type I interferon in vitro [81]. Moreover, the severe acute respiratory syndrome (SARS)-CoV, containing inactivation of ExoN by introducing D90A/E92A into the nsp14 resulted in attenuation of pathogenesis, but still protects mice from lethal challenge [82]. These experimental results inspire us to wonder about the immunogenicity and virulence of nsp15 in piglets.

PEDV nsp15 was identified as an endoribonuclease (EndoU) that plays a pivotal role in evading host response and viral replication [83]. PEDV nsp15 was could subvert the IFN response by the RNA degradation of TBK1 and IRF3 in HEK293T and IPEC-3J cells. H226, H241 and K282 and nsp15 were crucial for the IFN-β activity [84]. H226A, H241A and K282A in nsp15 probably provide a universal approach for generating live-attenuated vaccine candidates for emerging coronaviruses [85].

PEDV nsp15 possesses a 2′-O-methyltransferase (MTase) activity, which is highly conserved among coronaviruses. This MTase prevents CoV from being recognized by the intracellular sensor via capping of viral RNA [86]. Furthermore, PEDV nsp16 could promote virus replication by down-regulating innate immune mediated by RIG-1 and MDA5 in vitro [87].
Inactivation of PEDV 2’-O-MTase activity attenuated the virus in piglets and induced stronger type I and type III IFN responses in IPEC-DQ cells, which showed that np16 potentially provides a universal target for PEDV vaccine development [88].

2.2. Accessory protein

The ORF3 protein is the only PEDV accessory protein located between the S protein and E protein. ORF3, with ion channel activity, was predicted to harbor multiple transmembrane domains, and regulate viral replication and virulence [89,90]. Generally, the full-length ORF3 gene contains 675 nt in wild-type PEDV strains or 624 nt or 626 nt in cell-adapted or attenuated PEDV strains with 49 or 51 nt deletion, such as the classic strain CV777, DR13 and P-5V [91]. Nevertheless, different nucleotides deletion in ORF3 of 85–5 and AVCT12 strains led to early-termination of ORF3 [92,93] and the current study showed that viruses without ORF3 or with truncated ORF3 were completely attenuated in vivo [30,94]. Both full-length and truncated ORF3 could interact with the S protein to regulate viral replication [95]. What’s more, PEDV ORF3 also promoted viral replication also by detaining cells at the S-phase, facilitating vesicle formation, the ion channel activity, inhibiting apoptosis and promoting viral autophagy in vitro [89,96–99]. However, the replication of PEDV was suppressed in cells overexpressing vascular protein-sorting-associated protein 36 (VPS36) in a VPS36-ORF3 interaction manner [100].

2.3. Structural proteins

The PEDV S protein, a membrane glycoprotein located at the surface of the virus, exhibits a high degree of genetic diversity and plays a pivotal role in mediating viral entry, inducing neutralizing antibodies and viral virulence in vivo [101]. PEDV was divided into GI and GII types through phylogenetic analysis based on the complete S protein. The GI (e.g. CV777 and DR13) group consists of three subgroups (Gla, Glb and Glic) [102], while the GII group consists two subgroups (GIIa and GIIb). The S gene of GII PEDV contains typical insertion and deletion mutations compared to the GI PEDV, which may significantly affect the immunogenicity of the PEDV strains [103]. This may be the reason why the currently available commercial vaccines based on the attenuated CV777 strain failed to provide effective protection against epidemic GII PEDV strains [104]. Moreover, Lin et al further demonstrated that the neutralizing antibody titers in sera, the colostrum and the milk from the strains [104]. Moreover, Lin et al further demonstrated that the currently available commercial vaccines based on the attenuated CV777 genicity of the PEDV strains [103]. This may be the reason why the compared to the GI PEDV, which may significantly affect the immuno
capacity of the PEDV strains [111].

The PEDV E protein contains two intracellular sorting motifs, Yxxo and Yxxw, which will be helpful to the development of novel serological assays as well as the design of vaccines [131].

The M gene, with a total length of 681 bp, encodes an about 27–32 kDa protein. The M protein, a membrane glycoprotein localized throughout the cytoplasm, induced cell cycle arrest at the S-phase via the cyclin A pathway [132]. The PEDV M gene differs significantly between coronaviruses, but is relatively conservative among different PEDV strains [133,134]. Therefore, the M protein is a promising target for establishing various detection methods such as ELISA, RT-qPCR and RT-PCR [135,136]. The B cell epitope [129]. A novel variation with 16–20 aa deletion and an L25P mutation in the transmembrane domain of the PEDV E protein further upregulated the production of the ER stress indicator, improving the expression of IL-6 and IL-8, and promoted apoptosis in vitro [92]. In addition, PEDV E protein was confirmed to suppress type III IFN expression, but the specific molecular mechanism is still unknown [129]. The virulence of SARS-CoV lacking the E protein was significantly reduced in mice [130]. However, whether the PEDV E protein affects the viral virulence and whether the E protein is absolutely necessary for PEDV remain to be further studied. The E protein is also a diagnostic maker, which will be helpful to the development of novel serological assays as well as the design of vaccines [131].

The PEDV N protein is a highly conserved phosphoprotein, with only a few point mutations in different strains. However, the PEDV SH strain had a unique 12 aa (aa 399–410) deletion including an antigenic epitope of the N protein, whereas the deletion had no effect on the immunogenicity or pathogenicity of PEDV in mice and pigs [142]. The N protein has been associated with multiple functions in the viral life cycle, including the regulation of viral RNA synthesis, the packaging of the viral RNA in helical nucleocapsids, and virion assembly [141,144]. In the process of confrontation with host cells, the PEDV N protein not only inhibited cell proliferation by prolonging the S-phase cell cycle [145], but also antagonized the production of IFN-α by preventing nuclear translocation of NF-κB in IPEC-J2 cells [27,146]. The enhanced replication of PEDV in Vero B6 cells overexpressing the N protein may be related to the inhibition of host response by the N protein [147].

3. PEDV vaccines

3.1. Inactivated and attenuated live vaccines

PEDV traditional vaccines are mainly whole virus vaccines such as inactivated vaccine and live attenuated vaccines. Inactivated vaccines
offer several advantages, such as good safety profile and ease of production. However, the immunogenicity of inactivated vaccines could be altered in the inactivation process, which often require administration of multiple doses and booster injections [148]. Live attenuated vaccines are highly immunogenic and single immunization is usually sufficient to induce protective immunity. Nevertheless, the risk of reversion to a virulent wild type limits its applicability [149,150]. The key to developing vaccines is to select low-virulence, high-titer, and highly immunogenic strains. However, the isolation of PEDV strains in vitro is very difficult, especially for the pandemic variable strains, and even if the strains are isolated successfully, they may not necessarily have high titers. As early as 1993, the PEDV tissue-inactivated vaccine could provide pigs with immune protection for up to 6 months [151]. In 1994, the PEDV CV777 strain was attenuated via serial cell culture after 28 passages, providing protection for more than 80% of the pigs after immunization at the Houhai point [152]. Similarly, a PEDV vaccine strain could provide 90% protection after serial 90 passages in vitro [153]. In order to control the disease, China introduced the inactivated TGEV-PEDV bivalent vaccine in 1995 [154]. However, since the inactivated vaccine cannot replicate in the host, multiple immunizations and high immune dose were required. In March 2015, trivalent live attenuated vaccines (PEDV, TGEV and RV) were approved in China. In 2016, researchers produced an inactivated PEDV vaccine using a Korean PEDV epidemic KNU-141112 strain. In six and three weeks prior to farrowing, pregnant sows were immunized intramuscularly with the inactivated adjuvanted monovalent vaccine. The survival rate of pigs at the vaccination age were able to reach approximately 92% after the virulent strain challenge and diarrhea severity including viral shedding in feces was significantly reduced [155]. The highly virulent epidemic virus strain CT was serially passaged in Vero cells up to 120 passages (P120), and P120 had a higher viral titer and better cell adaptability with more obvious cytopathic effects. In addition, P120 showed significant reductions in clinical symptoms with 100% survival rate in piglets [2].

Although the strains’ virulence was attenuated after multiple passages, they strain probably lost partial or total ability to resist the pathogen’s challenge. Therefore, some researchers began to modify the PEDV strains with reduced viral virulence but high immunogenicity by reverse genetic operating systems to develop effective live attenuated vaccines. Table 2 summarizes candidates for PEDV live attenuated vaccines based on reverse genetic systems. Mutating the histidine(H) residue at the 226 site in PEDV EndoU into alanine(A) induced early and robust transcriptional activation of type I and type III IFNs, and significantly impaired the viral virulence [156]. Ablating the motif YxxoEKVHVQ in the C-Terminal and a 197-amino-acid region in the N-terminal domain of S protein likewise impaired the pathogenicity of the highly virulent PEDV icPC22A, but the effectiveness of protection requires further investigation [157,158]. Two recombinant PEDVs were generated by mutating K45-D129-K169-E202 into A (KDKE4A), which inactivated Z'-O-methyltransferase activity of PEDV nsp16, and abolished the endocytosis signal of the S protein (KDKE4A-SYA). The two mutant strains KDKE4A and KDKE4A-SYA replicated less efficiently but induced stronger type I and type III IFNs response in vitro. Moreover, the virulence of KDKE4A and KDKE4A-SYA was significantly reduced and the KDKE4A-SYA strain provided 80% protection rate for piglets [88]. In addition, nsp1, nsp2, nsp3, nsp5, nsp14 and E proteins modified strains are also the candidates for the development of PEDV live attenuated vaccines, since mutating certain sites on these genes significantly reduced the viral virulence, which has been demonstrated in other coronaviruses, such as MHV and SARS-CoV [16,17,159-164]. In a nutshell, introducing mutations into virulence genes and inactivating interferon antagonists by reverse genetic technology are effective strategies for developing effective PEDV live attenuated vaccines.

3.2. Subunit vaccine

Compared with whole virus vaccines, subunit vaccines have several advantages, including high safety, no contagious viral nucleic acids, and providing a uniform antigen of well-defined nature despite their low immunogenicity, which requires adjuvant or fusion with an immune enhancer to heighten immunogenicity [165,166]. Moreover, establishing a complete subunit vaccine production system is of great significance for the quick response of a sudden epidemic situation. For example, developing an oral vaccine based on the S protein of SARS-CoV-2 in a very short time was attributed to the mature platform of Saccharomyces cerevisiae in the team [167].

The PEDV S protein is the main target for developing subunit vaccines, which is inseparable from its multiple biological roles. In recent years, the researchers have expressed part of the PEDV S protein including COE and S1 or the full length of the S protein using E. coli, Bacillus subtilis, baculovirus, adenovirus, Lactobacillus, and transgenic plants expression systems. Mice or pigs immunized with these vaccines by oral, intramuscular, subcutaneous or intraperitoneal injection produced high levels of IgG and IgA. Table 3 summarizes the subunit vaccines based on the S protein in recent years. In addition, the

Table 2: Candidates for live attenuated vaccines based on reverse genetic systems.

| Proteins | Engineering genes | Animal | Virulence | Detection Indicators | References |
|----------|------------------|--------|-----------|----------------------|------------|
| Nonstructural proteins | | | | | |
| H226A of nsp15 | 7-day-old piglets (n – 8) | Attenuation | (1) Fecal shedding ↓ | [156] |
| KDKE/AAAA of nsp16 | 4-day-old piglets (n – 7-8) | Attenuation | (1) Mortality ↓ | [198] |
| (2) Fecal consistency scores ↓ | | (3) Villus atrophy ↓ | | |
| (4) Viral antigen in epithelial cells ↓ | | | | |
| F44A of nsp1 | 3-day-old piglets (n – 8-13) | Attenuation | (1) Fecal shedding ↓ | [185] |
| H226A and H241A of nsp15 | | (2) Clinical signs and fecal viral shedding ↓ | | |
| D129A of nsp16 | 5-day-old piglets (n – 3-5) | Attenuation | (1) Villus height to crypt depth (VH/CD) ratios ↓ | [157] |
| Deletion of YxxoEKVHVQ of S protein | | (2) Clinical signs and fecal viral shedding ↓ | | |
| Deletion of 197aa of S protein | 4-day-old piglets (n – 9-11) | Attenuation | (1) Diarrhea rate ↓ | [158] |
| Accessory proteins | Deletion of ORF3 | 2-week-old Piglets (n – 3-4) | Attenuation | (1) Diarrhea rate ↓ | [90] |
| | | | | (2) Mortality rate ↓ | |
| | | | | (3) Fecal virus shedding ↓ | |
| | | | | (4) VH/CD ratios ↑ | |
Table 3
Research progress of PEDV subunit vaccines in recent years.

| Systems            | Groups                      | Animal                        | Route | Amount of challenge | Detection Indicators                                                                 | References |
|--------------------|-----------------------------|-------------------------------|-------|--------------------|---------------------------------------------------------------------------------------|------------|
| Adenovirus         | (1) PBS                     | 4-week-old pigs (n = 5)       | IM    | 2 mL 107 TCID50    | (1) IgG and IgA in serum†                                                             | [199]      |
|                    | (2) Adenovirus-blank        |                               |       |                    | (2) Virus Neutralization (VN) Test†                                                    |            |
|                    | (3) Adenovirus-PEDV-S       |                               |       |                    | (3) Fecal viral shedding†                                                              |            |
|                    | (4) Inactivated virus       |                               |       |                    | (4) Fecal scores†                                                                     |            |
| Silkworm pupae     | (1) PBS                     | 4-week-old pigs (n = 5)       | Oral  | No                 | (1) IgG in serum*                                                                     | [200]      |
|                    | (2) The S-Bm cell           |                               |       |                    | (2) SlgA in cavity*                                                                    |            |
|                    | (3) the S-Bm pupae         |                               |       |                    |                                                                                      |            |
|                    | (4) the WT-Bm pupae        |                               |       |                    |                                                                                      |            |
| VSV                | (1) PBS                     | pregnant sows (~70 kg, n = 3) | IN IM | Piglets : 102 TCID50 | sows :                                                                                   | [201]      |
|                    | (2) rVSVMT-S                |                               |       |                    | (1) Neutralizing antibodies in the sera†                                                |            |
|                    |                             |                               |       |                    | (2) Neutralizing antibodies in colostrum or milk†                                     |            |
| L. lactis (CH/JLDH/2016) | (1) PBS               | 6-8-week-old mice (n = 20)   | Oral  | No                 |                                                                                      | [202]      |
|                    | (2) L. lactis (NZ3900)      |                               |       |                    |                                                                                        |            |
|                    | (3) pNZ8149/NZ3900         |                               |       |                    |                                                                                        |            |
|                    | (4) pNZ8149-S1/            |                               |       |                    |                                                                                        |            |
|                    | NZ3900                     |                               |       |                    |                                                                                        |            |
| Systems            | Groups                      | Animal                        | Route | Amount of challenge | Detection Indicators                                                                 | References |
|--------------------|-----------------------------|-------------------------------|-------|--------------------|---------------------------------------------------------------------------------------|------------|
| B. subtilis        | (1) PBS                     | 5-day-old pigs (n = 4)        | Oral  | No                 | (1) The area of PPs†                                                                  | [203]      |
|                    | (2) Inactivated PEDV        |                               |       |                    | (2) The vill length of ileum†                                                          |            |
|                    | (3) B. subtilis-COE         |                               |       |                    | (3) SlgA in saliva and feces (0, 12, 19, 26, 33 d)†                                   |            |
|                    |                             |                               |       |                    | (4) IgG in serum (0, 12, 19, 26, 33 d)†                                                |            |
|                    |                             |                               |       |                    | (5) SlgA + T cells and CD3+ T cells†                                                   |            |
|                    |                             |                               |       |                    | (6) CD3+CD8+T†                                                                        |            |
|                    |                             |                               |       |                    | (7) IL-10 and IL-10 levels†                                                            |            |
|                    |                             |                               |       |                    |                                                                                      |            |
|                    |                             |                               |       |                    |                                                                                      |            |
| HEK 293T (PEDV-PT) | (1) Control                 | 5-week-old pigs (n = 3)       | IM    | 5 × 105 TCID50     | (1) IgG and IgA in serum (0, 2, 4, 6 w)†                                              | [204]      |
|                    | (2) PEDV-S-LTB              |                               |       |                    | (2) SlgA titers in feces (0, 2, 4, 6 w)†                                               |            |
|                    |                             |                               |       |                    | (3) Neutralizing antibodies titers (0, 2, 4, 6 w)†                                     |            |
|                    |                             |                               |       |                    | (4) Fecal viral load (0, 1, 2, 3, 4, 5 dpi)†                                           |            |
|                    |                             |                               |       |                    | (5) Clinical scoring of fecal consistency (0, 1, 2, 3, 4, 5 dpi)†                       |            |
| E. coli (PEDV BMI) | (1) Control                 | mice                          | Oral  |                    | (1) IgG1, IgG2a and IgG2b in serum (7 w)†                                              | [205]      |
|                    | (2) NTD 231–501aa           |                               |       |                    | (2) SlgA in feces (7 w)†                                                               |            |
|                    | (3) NTD 231–501aa/CT        |                               |       |                    | (3) IgA + cells in the LP (7 w)†                                                      |            |
| HEK 293T (CV777)   | (1) PBS                     | 5-week-old mice               | SC    | No                 | (1) IgG in serum (0, 14, 21, 28, 42 d)†                                                | [206]      |
|                    | (2) CV777-S                 |                               |       |                    | (2) Neutralizing antibodies titers†                                                    |            |
|                    | (3) LNCIT2-S               |                               |       |                    |                                                                                      |            |
| Systems            | Groups                      | Animal                        | Route | Amount of challenge | Detection Indicators                                                                 | References |
|--------------------|-----------------------------|-------------------------------|-------|--------------------|---------------------------------------------------------------------------------------|------------|
| Baculovirus (PEDV-PT) | (1) Medium control         | mice                          | IM    | 5 mL 105 TCID50/mL | Mice :                                                                                | [207]      |
|                    | (2) S1-Bac                  |                               |       |                    | (1) IgG in serum (0, 14, 28 d)†                                                       |            |
|                    | (3) S-Bac                   |                               |       |                    | (2) Neutralizing antibodies (0, 14, 28 d) S1*, S1* Pigs                                |            |
|                    |                             |                               |       |                    | (1) IgG in serum (0, 14, 28 d)†                                                       |            |
|                    |                             |                               |       |                    | (2) Fecal SlgA (0, 14, 28 d) S1*                                                       |            |
|                    |                             |                               |       |                    | (3) Neutralizing antibodies (0, 14, 28 d) S1*, S1*                                   |            |
|                    |                             |                               |       |                    | (4) Body weights (7, 21, 35, 49 d)†                                                    |            |
|                    |                             |                               |       |                    | (5) Stool scores (every day) S1, S1†                                                   |            |
|                    |                             |                               |       |                    | (6) Fecal viral shedding (every day) S1, S1†                                            |            |
| E. coli (PEDV GDS01) | (1) PBS                    | 5-week-old pigs (n = 8)       | IM    | 7.5 mL 4 × 106 pfu/mL | (1) IgG and IgA in serum (14 d after the last immunization)†                             | [208]      |
|                    | (2) PBS (used for challenge)|                               |       |                    | (2) SlgA in saliva, snout and feces (14 d after the last immunization)†                 |            |
|                    | (3) rSF                     |                               |       |                    | (3) Neutralizing antibodies (14 d after the last immunization)†                          |            |
|                    | (4) COE                     |                               |       |                    | (4) IL-4 and IFN-γ in serum (14 d after the last immunization)†                          |            |
|                    | (5) COE/rSF                 |                               |       |                    | (5) PEDV shedding, fecal scores†                                                       |            |
|                    |                             |                               |       |                    | (6) Pathological lesion†                                                               |            |
| Systems | Groups | Animal | Route | Amount of challenge | Detection Indicators | References |
|---------|--------|--------|-------|--------------------|-----------------------|------------|
| ORFV (PEDV CO13) | (1) Control (MEM) | Primiparous gilts (n = 2) | IM | 2.5 x 102 TCID50 | (1) IgG, IgA and neutralizing antibodies in serum (0, 21, 28, 35, 42, 49, 54, 60, 63, 67, 70, 74 d) | [209] |
| ORFV-PEDV-S Systems Groups Animal Route Amount of | challenge | Baculovirus SPV (SQ2014) | (2) ORFV-PEDV-S | Oral | 5 mL 1 x 106 PFU/mL | (1) IgG and IgA in serum (5 d after immunization) | [210] |
| ORFV-PEDV-S (challenge) | (3) ORFV-PEDV-S | Live PEDV | (4) Live PEDV | (S 386-815aa) | | | |
| L. lactis | (1) PBS | 1-day-old piglets (n = 10-15) | Oral | 5 mL 1 x 106 PFU/mL | (1) IgG and IgA in serum (5 d after immunization) | [210] |
| | (2) pPG/L393 | | | | | |
| | (3) pPG-COE-DCpep/L393 | | | | | |
| | (4) HBcAg (149AA) | 8-week-old mice (n = 15) | IN | No | (1) IgG, IgA, IgG1, IgG2a and IgG2b in serum | [211] |
| | (2) rSF | | | | (2) SlgA in vagina | |
| | (3) COE | | | | (3) Serum neutralizing antibodies | |
| | (4) rSF-COE-3D | | | | (4) CD3+, CD4+ and CD8+ T cells in splenocytes | |
| | (5) rSF-COE-N | | | | | |
| | (6) rSF-COE-C | | | | | |
| | (1) PBS | 6-week-old mice (n = 6) | Oral | No | (1) IgG and neutralizing antibodies in serum (14, 35, 42 d) | [212] |
| | (2) NC8-pSiP409-pgaA* | | | | (2) IgG and neutralizing antibodies in feces (14, 35, 42 d) | |
| | (3) NC8/pSiP409/pgaA/S/DCpep | | | | | |
| | (4) NC8/pSiP409/pgaA-S/DCpep | | | | | |
| | (5) HBcAg + S2 (756SQYGQVKI771) | 7-week-old mice (n = 8) | IN IP | No | (1) IgG in serum (−1, 13, 27, 42 d) | [213] |
| | (4) HBcAg + S3 (1371GPRILQPY1377) | | | | (2) IgA in serum (−1, 13, 27, 42 d) | |
| | (5) HBcAg + M (195WAFYVR200) | | | | (3) IgG of anti-S1, S2, S3 and M in serum (42 d) | |
| | (6) HBcAg + S1/S2/S3/M | | | | (4) Neutralizing antibodies (42 d) S1, S2, S3 and M* | |
| Systems | Groups | Animal | Route | Amount of challenge | Detection Indicators | References |
|---------|--------|--------|-------|--------------------|-----------------------|------------|
| L. lactis | (1) PBS | 6-week-old mice (n = 15) | Oral | No | (1) IgG in serum (0, 7, 14, 21, 28, 35, 42 d) | [214] |
| | (2) L. lactis | | | | (2) SlgA in feces and vagina (0, 7, 14, 21, 28, 35 d) | |
| | (3) L. lactis/6D/COE | | | | (3) Neutralizing antibodies (35 d) | |
| | (4) L. lactis/GFP/6D/COE | | | | (4) Lymphocyte proliferation (35 d) | |
| SPV (SQ2014) (S 386-815aa) | (1) PBS | 1-month-old pigs (n = 3) | Oral SC | 1 mL 1 x 106 PFU IM | (1) IgG and IgA in serum (0, 7, 14, 21, 28, 35, 42, 49 d) | [215] |
| | (2) wtSPV | | | | (2) Neutralizing antibodies (0, 7, 14, 21, 28, 35, 42, 49 d) | |
| | (3) rSPV-St | | | | (3) The concentrations of IL-4 and IFN-γ (30 d) | |
| | (4) inactivated SQ2014 | | | | (4) Mortality | |
| | (5) inactivated CV777 | | | | | |
| Baculovirus | (1) PBS | 6-week-old mice (n = 10) | IM | No | (1) Neutralizing antibodies (2, 4, 6 w) | [216] |
| | (2) VLP | | | | (2) IFN-γ+ and IL4+T cells (4 w) | |
| | (3) Inactivated PEDV | | | | | |
| | (4) Adjutant Control | | | | | |
| | (2) Non-targeted PEDVAg/adjvant | | | | | |
| | (3) Langerin-targeted PEDV S/adjvant/TD | | | | | |
| | (4) Langerin-targeted PEDV S/adjvant/IM | | | | | |
| 293T PEDV MN (S 21-737aa) | (1) PBS | 4-week-old pigs (n = 7-8) | IM | No | (1) IFN-γ+CD4pos and CD8pos T cells (0, 21, 28, 35 d) | [217] |
| | (2) Inactivated PEDV-1 | | | | (2) IgG and IgA in serum (21, 28, 35, 42 d) | |
| | (3) Inactivated PEDV-2 | | | | (3) SlgA in feces (35 d) | |
| | (4) Neutralizing antibodies | | | | | |
indeterminate receptor-binding domains (RBDs) and the HR1 and HR2 regions in S2 of PEDV also are potential targets for developing subunit vaccines [168,169]. However, though there are some epitopes in the N and M protein, subunit vaccines based on the PEDV N and M proteins have not yet been reported [137,170]. Furthermore, whether the subunit vaccine based on PEDV non-structural proteins could induce a protective response also needs further verification.

### 3.3. Nucleic acid vaccines

Although the cycle of developing inactivated vaccines is short, inactivated vaccines immunogenicity is poor. Live attenuated vaccines have good immunogenicity, but with poor security and long development cycle. Continual mutation of the PEDV genome, mixed infection with other viruses and huge economic losses all require effective vaccines with a very short development cycle. Hence, nucleic acid vaccines emerged, including DNA vaccines and mRNA vaccines. The advantages of these vaccines are low cost, high safety, short lead time and simple design [171,172]. The most important is that the established platform is universal. Once the platform has been established, all that is required is the synthesizing and inserting of the sequence of the core neutralizing antigen gene into an appropriate expression vector, which might be useful for the development of vaccines against emerging pandemic infectious diseases in a considerably shortened time [173]. However, the bivalent DNA vaccine generated by combining PEDV with an RV or TGEV have been developed but not yet been applied to clinical trials, possibly because of the poor immunogenicity [174,175]. Although the effectiveness of DNA vaccines has been improved by optimizing codons, selecting appropriate promoters, optimizing plasmid vector backbones, and adding molecular adjuvants, some breakthroughs are still required to be made to allow DNA vaccines to play a more significant role in preventing disease [172]. RNA vaccines have great application prospects. Five advanced candidates have recently been moved into clinical development, including mRNA-1273 from Moderna, Ad5-nCoV from CanSino Biologics, INO-4800 from Inovio, LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute [176]. As early as 2014, the company of Harrisvaccines in the United States used its SirraVaxSM technology to produce PEDV mRNA vaccines, and this platform technology is conditionally licensed in the USA. Compared to DNA vaccines, mRNA vaccines possess higher immune potency but more instability in vivo [171]. Self-amplifying RNA (saRNA) encoding the alphaviral replicase and a gene of the viruses enables replication of the RNA in the cytoplasm [177,178]. The sa-RNA vaccines based on influenza hemagglutinin was more effective than the mRNA vaccine in mice [179] and the sa-RNA vaccines encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle also induced high neutralizing antibody titers in mice [180]. Therefore, the application of sa-RNA vaccines and corresponding delivery vectors will probably break the bottlenecks in the development of PEDV or other coronaviruses mRNA vaccines.

### 4. Conclusion

The current PEDV vaccines may have failed to prevent the PEDV epidemic situation because the virus is constantly variable and the vaccines cannot induce sufficient mucosal immunity. The S IgA secreted by intestinal mucosal epithelial cells was able to neutralize viruses at the invasion site. On the other hand, SlgA in the colostrum and milk of sows play a decisive role in protecting neonatal suckling piglets against PEDV. At present, two strategies have been used to induce mucosal immunity. The first one involves applying suitable carriers for delivering vaccines by mucosal routes; a whole PEDV attenuated strain entrapped in the enteric material hydroxypropyl methyl cellulose phthalate (HPMCP) successfully induced both mucosal immunity and systemic immunity after oral immunization in weaned piglets [181,182]. PEDV killed vaccine antigens (KAg) entrapped in PLGA particles was delivered intranasally to sows at 28 and 14 days prior to farrowing. Pregnant sows immunized with PLGA-KAg had the highest serum IgG and IgA levels, colostrum IgA antibody titers, and the strongest cellular immune response [183]. The second was that intramuscularly administrating vaccines with appropriate adjuvants. Recently, the researchers developed an inactivated vaccine that could induce SlgA and IgG in S-week-old pigs only by intramuscular injection of inactivated PEDV antigen combined with CCL25, CCL27 and CCL28 proteins [184].

In summary, the application of reverse genetic operating systems, mucosal immune enhancement adjuvants and mucosal delivery vehicles may have a great significance for the development of both traditional vaccines and new vaccines of PED.

### Declaration of competing interest

The authors declare no conflict of interest.

### Acknowledgement

This work was supported by the National Key R&D Project of China.
References

[1] Y. Li, Q. Wu, L. Huang, C. Yuan, J. Wang, Q. Yang, An alternative pathway of emergency PEDV dissemination from nasal cavity to intestinal mucosa in swine, Nat. Commun. 9 (2018) 3811.

[2] Y. Wu, W. Li, Q. Zhou, Q. Li, Z. Xu, H. Shen, F. Chariot, and Z. Li et al. [24] L. Verstrepen, T. Bekaert, T.L. Chau, J. Tavernier, A. Chariot, R. Beyaert, TLR-4, [23] J. Napetschnig, H. Wu, Molecular basis of NF-kappaB signaling, Annu. Rev. Immunol. 87 (2017) 111–126.

[22] M.S. Hayden, S. Ghosh, NF-kappaB, the first quarter-century: remarkable progress and outstanding questions, Genes Dev 26 (2012) 203.

[21] R. Zust, L. Cervantes-Barragan, T. Kuri, G. Blakqori, F. Weber, B. Ludewig, [19] R. Siegel, J. Eskdale, G. Gallagher, Regulation of IFN-lambda1 promoter activity and infection outcomes in naive conventional intestinal and weaned pigs, PLoS One 10 (2015), e0193266.

[4] S. Leidenberger, C. Schroder, L. Zani, A. Aute, M. Pinette, A. Ambagala, V. Nikolos, H. de Smit, M. Beer, S. Blome, Virulence of current German PEDV strains in suckling pigs and investigation of protective effects of maternally derived antibodies, Sci. Rep. 7 (2017) 10825.

[9] H. Lin, L. Chen, L. Gao, X. Yuan, Z. Ma, H. Fan, Epidemic strain YC2014 of porcine epidemic diarrhea virus could provide piglets against homologous challenge, Virol. J. 13 (2016) 68.

[6] C. Lee, Porcine epidemic diarrrhea virus: an emerging and re-emerging epizootic swine disease, Virol. J. 12 (2015) 192.

[1] O. Wichit, W. Li, J. Williams, T.J. Medema, R.W. Bubboltz, F.J. van Kuppeveld, P.J. Rottier, B.J. Bosch, Proteolytic activation of the porcine epidemic diarrrhea coronavirus spike fusion protein by trypsin in cell culture, J. Virol. 88 (2014) 7952–7961.

[2] W. Li, F.J.M. van Kuppeveld, Q. He, P.J.M. Rottier, B.J. Bosch, Cellular entry of the porcine epidemic diarrrhea virus, Virus Res. 226 (2016) 117–127.

[3] P.C. Woo, Y. Huang, S.K. Lau, K.-Y. Yuen. Coronavirus genomics and bioinformatics analysis, Viruses 2 (2010) 1804–1820.

[4] X. Lei, X. Dong, R. Ma, W. Wang, X. Xiao, Z. Tian, C. Wang, Y. Li, L. Ren, F. Guo, Z. Zhao, Z. Zou, X. Jiang, J. Wang, Activation and evasion of type I interferon responses by SARS-CoV-2, Nat. Commun. 11 (2020) 3810.

[5] K.G. Lokugamage, K. Narayanan, C. Huang, S. Makino, Severe acute respiratory syndrome coronavirus nonstructural protein 3a is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation, J. Virol. 86 (2012) 13598–13608.

[6] W. Kamitani, C. Huang, K. Narayanan, K.G. Lokugamage, S. Makino, A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nplp1 protein, Nat. Struct. Mol. Biol. 16 (2009) 1134–1140.

[7] C. Huang, K.G. Lokugamage, J.M. Rozovics, K. Narayanan, B.L. Semler, S. Makino, SARS coronavirus nplp1 protein induces template-deendent endonucleolytic cleavage of mRNAs viral mRNAs are resistant to nplp1-induced RNA cleavage, PLoS Path 7 (2011), e1002433.

[8] J.M. Jimenez-Guardano, J.A. Regla-Nava, J.L. Nieto-Torres, M.L. DeDiego, C. Castano-Rodriguez, S. Perlman, L. Enjuanes, papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon synthesis in porcine kidney cells, J. Biol. Chem. 282 (2007) 32208–32221.

[9] L. Yu, J. Dong, Y. Wang, Y. Li, F. Diao, L. Zhang, P. Tien, B.J. Bosch, Proteolytic activation of the porcine epidemic diarrhea virus nonstructural protein 1 for innate immune evasion, Virology 510 (2020) 1249–1255.

[10] A.M. Mielech, Y. Chen, A.D. Mesecar, S.C. Baker, Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities, Virus Res 194 (2016) 184–190.

[11] K. Ratia, K.S. SaiKato, B.R. Zimmerman, N. Barretto, S.C. Baker, R.C. Stevens, A.D. Mesecar, Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5717–5722.

[12] A. Kanjanahualai, S.C. Baker, Identification of mouse hepatitis virus papain-like proteinase 2 activity, J. Virol. 74 (2000) 7911–7921.

[13] E.J. Snijder, E. Drecory, J. Ziebuhr, The nonstructural proteins directing coronavirus RNA synthesis and processing, Adv. Virus Res. 96 (2016) 59–126.

[14] S.C. Devanji, N. Wang, Z. Chen, Z. Chen, M. Tseng, N. Barretto, R. Lin, C.J. Peters, C.T.-K. Tseng, S.C. Baker, Regulation of IFR-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus, J. Biol. Chem. 282 (2007) 32208–32221.

[15] L. Sun, Y. Xing, C. Chen, Z. Zheng, Y. D. Nichols, M.A. Clementz, B. S. Banach, K. Li, S.C. Baker, Z. Chen, Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling, PLoS One 7 (2012), e30802.

[16] B. Zhong, Y. Yang, S. Li, Y.Y. Wang, Y. Li, F. Diao, C. Lei, X. He, L. Zhang, P. Tien, H.B. Shu, The adaptor protein MITA links virus-sensing receptors to IFR3 transcription factor activation, Immun. 29 (2009) 538–550.

[17] W. Sun, Y. Li, L. Chen, H. Chen, F. You, Y. Zhou, Z. Bai, D. Chen, Z. Jiang, ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 8653–8658.

[18] Y. Xing, J. Chen, J. Tu, B. Zhang, X. Chen, H. Shi, S.C. Baker, L. Feng, Z. Chen, The papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase, J. Gen. Virol. 94 (2013) 1554.

[19] L. Sun, Y. Xing, C. Chen, Z. Zheng, Y. D. Nichols, M.A. Clementz, B. S. Banach, K. Li, S.C. Baker, Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling, PLoS One 7 (2012).

[20] Y. Wang, A. Sun, Y. Sun, Z. Tia, X. Guo, Z. Hao, L. Zhang, X. Qiao, W. Cui, L. Tang, X. Xu, Y. Li, L. Wang, Porcine transmissible gastroenteritis virus inhibits N-kappaB activity via nonstructural protein 3 to evade host immune system, J. Virol. 16 (2019) 97.

[21] L. Yu, J. Dong, Y. Wang, Y. Li, Z. Zhang, L. Liang, L. Wang, C. Song, Porcine epidemic diarrhea virus nsp4 induces pro-inflammatory cytokine and chemokine expression inhibiting viral replication in vitro, Arch. Virol. 164 (2019) 147–157.

[22] J. Snijder, E.J. Snijder, A.D. Mesecar, B.E. Gorbalenya, Virus-encoded proteases and proteolytic processing in the Nidovirales, J. Gen. Virol. 80 (2000) 853–879.

[23] Z. Jiebuhr, The coronavirus replicase, Curr. Top. Microbiol. Immunol. 287 (2005) 97–134.

[24] V. Thiel, K.A. Ivanov, A. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weisnich, E. J. Snijder, H. Rabenau, H.W. Doerr, A.E. Gorbalenya, Z. Jiebuhr, Mechanisms and enzymes involved in SARS coronavirus genome generation, J. Gen. Virol. 84 (2003) 2305–2315.

[25] F. Gao, H.Y. Ou, L.L. Chen, W.X. Zheng, C.T. Zhang, Prediction of protease cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes, FEBS Lett 553 (2003) 451–456.

[26] L. Durnam, K.V. Holmes, The molecular biology of coronaviruses, Adv. Virus Res. 82 (2013) 35–112.
K. Anand, J. Ziebuhr, J. Mesters, R. Hilgenfeld, Coronavirus main proteinase (3CLpro): structure for design of anti-SARS drugs, Science 300 (2003) 1763–1767.

H. Yang, M. Yoneyama, T. Fujita, RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity, Cytokine Growth Factor Rev 18 (2007) 545–551.

D. Wang, L. Fang, Y. Shi, H. Zhang, L. Gao, G. Peng, H. Chen, K. Li, S. Xiao, Porcine epidemic diarrhea virus 3C-like protease regulates its interferon antagonism by blocking NEMO, J. Virol. 90 (2016) 2090–2101.

G. Ye, F. Deng, Z. Shen, R. Luo, L. Zhao, S. Xiao, Z.F. Fu, G. Peng, Structural basis for the dimerization and substrate recognition specificity of porcine epidemic diarrhea virus 3C-like protease, Virology 494 (2016) 225–235.

J. Anand, J. Ziebuhr, F. Wuthrich, M. Bartlam, R. Hilgenfeld, Coronavirus main proteinase (3C-like protease): structural basis for design of anti-SARS drugs, Microbiol. 149 (2020) 104553。

K. Anand, A. Heigl, C. Zehenthuber, Z. Zhou, H. Yang, W. Xie, L. Fang, L. Yao, D. Pei, R. Luo, Z. Li, S. Xiao, Z. Wu, P. Yin, J. Li, Y. Song, G. Peng, Identification of two antiviral inhibitors targeting 3C-like serine protease for the dimerization and substrate recognition specificity of porcine epidemic diarrhea virus 3C-like protease, Virology 494 (2016) 225–235.

K. Anand, J. Ziebuhr, Human coronavirus 229E nonstructural protein 13: a single-stranded RNA-binding subunit unique in the RNA virus world, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13191–13195.

H. Yang, W. Xie, X. Xue, K. Yang, J. Ma, W. Liang, Q. Zhao, Z. Zhou, D. Pei, J. Ziebuhr, R. Hilgenfeld, K.Y. Yuen, L. Wong, G. Shen, Z. Chen, Z. Ma, M. Bartlam, Z. Rao, Design of wide-spectrum inhibitors targeting coronavirus main proteinases, PloS Biol 3 (2005) e324.

X. Zuo, H. Hu, Y. Yang, F. Xue, Z. Wu, W. Shen, J. Li, Z. Zhou, Y. Deng, Q. Zhao, X. C. Xue, M. Li, M. Zhang, L. Rao, Structures of two coronavirus main proteinases: implications for substrate binding and antiviral drug design, J. Virol. 82 (2008) 2515–2527.

X. Deng, S.E. StJohn, H.L. Osswald, A. O, X. Xue, H. Yu, H. Yang, W. Xie, L. Fang, X. Zuo, Structures of two coronavirus main proteinases: implications for substrate binding and antiviral drug design, J. Virol. 82 (2008) 2515–2527.

Y. Zhai, F. Fan, X. Li, H. Fang, X. Mu, M. Bartlam, Z. Rao, Insights into SARS-CoV transcription and replication from the structure of the nsp8–nsp9 hexamer, Nat. Struct. Mol. Biol. 12 (2005) 980–996.

Y. Xiao, Q. Ma, T. Restle, W. Wang, D.I. Svergun, R. Ponnusamy, G. Szakalik, R. Hilgenfeld, Nonstructural proteins 7 and 8 of feline coronavirus form a 2:1 heterotetramer that exhibits primer-independent RNA polymerase activity, J. Virol. 86 (2012) 4444–4454.

L. Subisi, C.C. Posthuma, A. Collet, J.C. Zevenhoven-Dobbe, A.E. Gorbalenya, E. Decroy, E.J. Snijder, B. Canard, An ever-increasing number of coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance, J. Virol. 88 (2014) 11188–11198.

I. Imerit, J.C. Guillot, J.M. Bourhis, C. Busseta, B. Coutard, M.P. Egloff, F. Ferron, A.E. Gorbalenya, B. Canard, A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus, EMBO J 25 (2006) 4933–4942.

Y. Hou, H. Ke, J. Kim, D. Yoo, Y. Su, P. Boley, J. Chepngeno, A.N. Vlasova, L. B. Graham, J. Q. Wang, Endogenous GC376, an interferon antagonism by cleaving NEMO, J. Virol. 90 (2016) 2090–2101.

Y. Wu, H. Zhang, Z. Gao, Y. Yu, L. Li, H. Shi, D. Shi, L. Guo, L. Feng, Porcine epidemic diarrhea virus nsp15 antagonizes interferon signaling by RNA degradation of TBK1 and IRF3, Viruses 12 (2020).

Y. Meng, A. Debnath, T. Warnecke, J. Lu, N. Jr, W. Richardson, G. Dharmalingam, C. S. Pierson, R. K. Smith, A. Khan, J. Ziebuhr, G. Peng, Porcine epidemic diarrhea virus suppresses type I and type III interferon responses, J. Virol. 93 (2019).

V.D. Menachery, K. Debbsink, R.S. Baric, Coronavirus non-structural protein 16: evasion of attenuation, and possible treatments, Virus Res 194 (2014) 191–199.

P. Shi, Y. Su, R. Li, Z. Liang, S. Dong, J. Huang, PEDV nsp16 negatively regulates innate immunity to promote viral proliferation, Virus Res 265 (2019) 57–66.

Y. Hou, H. Ke, J. Jin, D. Yoo, Y. Su, P. Boley, J. Chepngeno, A.N. Vlasova, L. B. Graham, J. Q. Wang, Endogenous GC376, an interferon candidate vaccine via inactivation of the viral 2‘-O-methyltransferase and the endocytosis signal of the spike protein, J. Virol. 93 (2019).

R. Hu, L. Cui, Y. Xu, H. Shi, H. Hui, W. Yu, X. Guo, C. Bian, W. B. Fischer, W. Schwarz, L. Feng, B. Sun, PEDV ORF3 encodes an ion channel protein and regulates virus production, FEBS Lett 586 (2012) 384–391.

A. Beall, B. Yount, C.M. Lin, Y. Hou, Q. Wang, L. Saf, R. Baric, Characterization of a pathogenic full-length CDNA clone and transmission model for porcine epidemic diarrhea virus strain PC22A, mBio 7 (2016) e01451–15.

K. Chen, C. Wang, H. Shi, H. Qiu, S. Liu, X. Chen, Z. Zhang, L. Feng, Molecular epidemiology of porcine epidemic diarrhea virus in China, Arch. Virol. 155 (2020) 1911–1922.

M. Sun, J. Ma, Z. Yu, Z. Pan, C. Lu, H. Yao, Identification of two mutation sites in spike protein and envelope proteins mediating optimal cellular infection of porcine epidemic diarrhea virus from different pathways, Vet. Res. 48 (2017) 44.

J. Feng, Z. Shi, J. Shao, J. Chen, F. Wang, W. Liu, Y. Gao, X. Wang, G. Peng, Identification of two mutation sites in ORF5 of porcine epidemic diarrhea virus recovered from a full-length infectious CDNA clone, J. Gen. Virol. 96 (2015) 2206–2218.

S. Lee, K.Y. Son, Y.H. Hoi, C.H. Choi, J.Y. Yoon, C. Lee, Genetic characteristics, pathogenicity, and immunogenicity associated with cell adaptation of a virulent genotype 2b porcine epidemic diarrhea virus, Vet. Microbiol. 207 (2017) 248–258.

M. Sun, J. Ma, Z. Yu, Z. Pan, C. Lu, H. Yao, Identification of two mutation sites in spike protein and envelope proteins mediating optimal cellular infection of porcine epidemic diarrhea virus from different pathways, Vet. Res. 48 (2017) 44.

D. Zou, J. Xu, X. Duan, X. Xu, P. Li, L. Cheng, L. Zheng, X. Li, Y. Zhang, X. Wang, Porcine epidemic virus nsp13 protein contains endoplasmic reticulum stress to facilitate autoplogy, Vet. Microbiol. 235 (2019) 209–219.

F. Si, X. Hu, C. Wang, B. Chen, R. Wang, S. Dong, R. Yu, Z. Li, Porcine epidemic diarrhea virus (PEDV) ORF3 enhances viral proliferation by inhibiting apoptosis in infected cells, Viruses 12 (2020) 218.

C. Kaworthoith, Q. He, A. Jongkaewwattana, The accessory protein ORF3 contributes to porcine epidemic diarrhea virus replication by direct binding to the spike protein, Viruses 10 (2018).

S. Ye, Z. Li, F. Chen, S.G. Poth, C. Hui, R. Q. He, Porcine epidemic diarrhea virus ORF3 gene prolongs S-phase, facilitates formation of vesicles and promotes the proliferation of attenuated PEDV, Virus Gene 51 (2015) 385–392.

C. Kaworthoith, Y. Yingying, C. Manukul, A. Jongkaewwattana, Porcine epidemic diarrhea virus (PEDV) ORF3 interacts in vitro reveals inhibition of PEDV replication by cellular VPS36 protein, Viruses 11 (2019).

Y. Chen, Z. Zhang, J. Li, Y. Gao, L. Zhou, X. Ge, J. Han, X. Guo, H. Yang, Porcine epidemic diarrhea virus S1 protein is the critical inducer of apoptosis, Virol. J. 15 (2018) 170.
J. Yu, X. Chai, Y. Cheng, G. Xing, A. Liao, L. Du, Y. Wang, J. Lei, J. Gu, J. Zhou, F.C. Hsueh, C.N. Lin, H.Y. Chiou, M.Y. Chia, M.T. Chiou, T. Haga, C.F. Kao, Y. D. Wrapp, J.S. McLellan, The 3.1-angstrom cryo-electron microscopy structure of the ACE2 receptor, Nature 581 (2020) 215.

B. Li, J. Ge, Y. Li, Porcine aminopeptidase N is a functional receptor for the PEDV S1 subunit of spike protein from a current highly virulent porcine epidemic diarrhea virus isolate, Transgenic Res. 28 (2019) 21.

C. Chang, C.Y. Chang, C.R. Jeng, Updated phylogenetic analysis of the spike gene of porcine epidemic diarrhea virus in Taiwan, Transbound Emerg. Dis. 67 (2019) 417.

Z. Li et al., Molecular characteristics of the spike gene of porcine epidemic diarrhea virus strains in Eastern China in 2016, Virus Res 247 (2018) 47–54.

W. Li, H. Fang, X. Wang, D. Y. T. Zhang, D. S. Feng, Y. Q. Peng, Y. Chen, A. Li, F. Zhang, Q. Wu, Y. Ye, Comparison and evaluation of conventional RT-PCR, SYBR green I and TaqMan real-time RT-PCR assays for the detection of porcine epidemic diarrhea virus, Mol. Cell. Probes 33 (2017) 36–41.

J. Z. Zhang, J. Chen, H. Shi, D. Shi, L. Feng, B. Yang, Identification of a conserved linear B-cell epitope in the M protein of porcine epidemic diarrhea virus, Virol. J. 9 (2012) 225.

D. J. Pulford, P. Britton, Expression and cellular localisation of porcine transmissible gastroenteritis virus N and M proteins by recombinant vaccinia viruses, Viruses 18 (2016) 203–217.

C. A. de Haan, L. Kuo, P.S. Masters, H. Venema, P.J. Rottier, Porcine coronavirus particle assembly: primary structure requirements of the membrane protein, J. Virol. 72 (1998) 6838–6850.

E. C. Bos, W. Luytjes, H. van de Meulen, H.K. Koerten, W.J. Spaan, The production of recombinant infectious cDNA-particles of a murine coronavirus in the absence of helper virus, Virology 218 (1996) 52–60.

H. Vennema, G.J. Godeke, J.W. Rossen, W.F. Voorhout, M.C. Horzinek, D. J. Opstelten, P.J. Rottier, Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope gene proteins, EMBO J 15 (1996) 2020–2028.

X. W. Wang, M. Wang, J. Zhan, Q.-Y. Liu, L.-F. Fang, C.-Y. Zhao, P. Jiang, Y.-F. Li, J. Bai, Pathogenicity and immunogenicity of a new strain of porcine epidemic diarrhea virus containing a novel deletion in the N gene, Vet. Microbiol. 240 (2020) 108511.

Y. W. Tan, S. Fang, H. Fan, J. Lescar, D.X. Liu, Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells, Nucleic Acids Res 47 (2019) 5932–5947.

H. Fan, A. Ooi, Y.W. Tan, S. Fang, D.X. Liu, J. Lescar, The nucleocapsid protein of coronavirus infectious bronchiitis virus: crystal structure of its N-terminal domain and multimerization properties, Structure 13 (2005) 1869–1876.

X. X. Hu, H. Zhang, Q. Zhang, Y. Huang, D. Tong, Porcine epidemic diarrhea virus N protein promotes S-phase cell cycle, induces endoplasmic reticulum stress, and up-regulates interleukin-8 expression, Vet. Microbiol. 164 (2013) 212–221.

Y. Shan, Z. Liu, G.-w. Li, C. Chen, H. Luo, Y.-j. Liu, X.-h. Zhuo, X.-f. Shi, W.-h. Fang, X.-l. Li, Nucleocapsid protein from porcine epidemic diarrhea virus isolates can antagonize interferon-α production by blocking the nuclear factor-κB nuclear translocation, J. Biotechnol. Sci. B 19 (2018) 570–580.

B. Li, J. Ge, Y. Li, Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus, Virology 365 (2007) 167–172.

J. Zhang, L. Guo, L. Yang, J. Xu, L. Zhang, L. Feng, H. Chen, Y. Wang, Metalloprotease ADAM17 regulates porcine epidemic diarrhea virus infection by modifying aminopeptidase N, Virology 517 (2018) 24–29.

C.-M. Ji, B. Wang, J. Zhou, Y.-W. Huang, Aminopeptidase-N-independent entry of porcine epidemic diarrhea virus into Vero or porcine small intestine epithelial cells, Virology 517 (2018) 16–25.

W. Li, H. Luo, H. Fang, X. K. van Kuppevelt, P.J. Rottier, B.-J. Bosch, Aminopeptidase N is not required for porcine epidemic diarrhea virus entry, Cell. Viro 235 (2017) 6–13.

K.-M. Whitworth, R.B. Rowland, Y. Petrovans, M. Sheahan, A.G. Cino-Ozuna, F. F. Hesse, A. Mileham, S. M. swing, Resistance to coronavirus infection in aminopeptidase N-deficient pigs, Tranz Res. 28 (2018) 21–32.

W. D. X. Ge, D. Chen, J. Li, Y. Cai, J. Deng, L. Zhou, X. Guo, J. Han, H. Yang, The S gene is necessary but not sufficient for the virulence of porcine epidemic diarrhea virus novel variant strain BZH211C, J. Virol. 92 (2018) e00603–e00618.

C.-F. Kao, H.-W. Chang, Investigation of the role of the spike protein in_reverseing the virulence of the highly virulent taiwan porcine epidemic diarrhea virus by screening 52 strains in an attenuated conventional cell assay, J. Virol. 80 (2016) 41.

T. Suzuki, Y. Terada, T. J. van Kuppevelt, P.J. Rottier, B.-J. Bosch, Aminopeptidase N is not required for porcine epidemic diarrhea virus entry, Cell. Viro 235 (2017) 6–13.

K. Shirato, M. Maejima, M.T. Isham, A. Miyazaki, M. Kawase, S. Matsuyama, F. Taguchi, Porcine aminopeptidase N is not a cellular receptor of porcine epidemic diarrhea virus, but promotes its infectivity via aminopeptidase activity, J. Gen. Virol. 97 (2016) 2528–2539.

D. J. Cruz, C.J. Kim, H.J. Shin, The GPR1QMP motif located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus, Virus Res. 132 (2008) 192–196.

D. Sun, L. Feng, H. Shi, J. Chen, X. Cui, H. Chen, S. Liu, Y. Tong, Y. Wang, Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein from a recombinant chimeric virus, Vet. Microbiol. 131 (2008) 73–81.

F. A. Okida, S. Lawson, A. Singrey, J. Nelly, K.S. Hain, L.R. Joshi, J. Christopher-Hennings, E.A. Nelson, D.G. Diehl, The S glycoprotein subunit of porcine epidemic diarrhea virus contains immunodominant neutralizing epitopes, Virology 509 (2017) 185–194.

N. Kong, Q. Meng, Y. Jiao, Y. Wu, Y. Zuo, H. Wang, D. Sun, D. Song, H. Zhai, W. Tong, H. Cheng, H. Yu, G. Tong, Y. Xu, T. Shen, Identification of a novel B-cell epitope in the spike protein of porcine epidemic diarrhea virus, Virol. J. 17 (2020) 19.

L. Kuo, P.S. Masters, The small envelope protein E is not essential for murine coronavirus replication, J. Virol. 77 (2003) 4597–4608.

D. Britan, B. Lamb, Coronavirus genome structure and replication, Curr. Top. Microbiol. Immunol. 287 (2005) 1–30.

X. Xu, H. Zhang, Q. Zhang, J. Dong, Y. Liang, Y. Huang, H.-J. Liu, D. Tong, Porcine epidemic diarrhea virus E protein causes endoplasmic reticulum stress and up-regulates interleukin-8 expression, Virol. J. 10 (2013) 26.
[154] S. Ma, M. Wang, L. Feng, W. Li, Development of bi-combined inactivated vaccine against transmissible gastroenteritis virus and porcine epidemic diarrhea virus, Chin. Anim. Infect. Dis. 16 (2019) 33-39.

[155] P.-S. Baek, H.-W. Choi, S. Lee, J.-I. Yoon, Y.J. Lee, S. Lee, C. Lee, Efficacy of an inactivated genotype 2b porcine epidemic diarrhea virus vaccine in neonatal piglets, Vet. Immunol. Immunopathol. 174 (2016) 45-49.

[156] X. Deng, A. van Gennip, A.C. Buckley, A. Pillatzki, K.M. Lager, K.S. Faaberg, S.C. Baker, Coronavirus endonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses, J. Virol. 93 (2019) e00200-00 e00200-00.

[157] Y. Hou, T. Medlila, X. Gao, L.J. Saif, Deletion of both the tyrosine-based endoplasmic reticulum signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs, J. Virol. 93 (2019) 13017-13026.

[158] R.L. Graham, A.C. Sims, S.M. Brockway, S.R. Baric, M.R. Denison, The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication, J. Virol. 79 (2005) 4907-4917.

[159] A.R. Fehr, J. Athrner, R. Channappanavar, M.V. Phillips, D.K. Meyerholz, S. Perlman, The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis, J. Virol. 89 (2015) 1523-1536.

[160] X. Deng, S.E. Sloderbrose, S.C. Baker, A. O’Hare, A.S. Sanach, K. Sheenan, J. Athrner, A. Pillatzki, K.M. Lager, D. Marthaler, A.L. Douglas, L. Koch, A platform for RNA virus cloning, Nat. Rev. Genet. 21 (2020) 388.

[161] Y. Hou, C.-M. Lin, M. Yokoyama, B.L. Yount, D. Marthaler, A.L. Douglas, L. Koch, A platform for RNA virus cloning, Nat. Rev. Genet. 21 (2020) 388.

[162] Y. Hou, T. Meduila, X. Gao, L.J. Saif, Deletion of both the tyrosine-based endoplasmic reticulum signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs, J. Virol. 93 (2019) 13017-13026.

[163] L. Du, W. Tai, Y. Zhou, S. Jiang, Vaccines for the prevention against the threat of gastroenteritis virus and porcine epidemic diarrhea virus, Braz. J. Microbiol. 50 (2019) 279-286.

[164] S. Fang, B. Chen, F.P. Tay, B.S. Ng, D.X. Liu, An arginine-to-proline mutation in a Sarabal domain with undefined functions within the helicase protein (Nsp13) is lethal to the coronavirus infectious bronchitis virus in cultured cells, Virology 358 (2007) 351-358.

[165] H. Lin, B. Li, M. Liu, H. Zhou, K. He, H. Fan, Nonstructural protein 6 of porcine epidemic diabetes virus upregulates pro-inflammatory cytokine and chemokine expression inhibiting viral replication in vitro, Arch. Virol. 164 (2019) 1793-1802.

[166] S. Fang, B. Chen, F.P. Tay, B.S. Ng, D.X. Liu, P. Zhou, Y. Zhang, Y. Wang, Evaluation of the efficacy of a recombinant lactococcus lactis strain expressing a variant porcine epidemic diarrhea virus S1 gene and its immunogenicity analysis in mice, Viral Immunol. 32 (2019) 144-150.

[167] T. Thanh Le, Z. Andreadakis, A. Kumar, R. Gomez Roman, S. Tollefsen, M. Saville, J. Shattock, Self-amplifying RNA vaccines give equivalent protection against influenza to vaccines but at much lower doses, Mol. Ther. 26 (2018) 446-455.

[168] P.F. McKay, K. Hu, A.K. Blakney, K. Sammann, J.C. Brown, R. Penn, J. Zhou, C. Boutron, P. Kober, P.J.C. Lin, C. Barbosa, Y.K. Tam, W.S. Barclay, R. Shattock, Self-amplifying RNA viruses as an alternative to SARS-CoV-2 vaccines: Challenges and opportunities, J. Virol. 95 (2021) 1452-1459.

[169] A.B. Vogel, L. Lambert, E. Kinneir, D. Busse, S. Erbar, K.C. Reuter, L. Wickle, M. Perko, T. Biber, J. Haas, S. T. Reed, Self-amplifying RNA vaccines give equivalent protection against influenza to vaccines but at much lower doses, Mol. Ther. 26 (2018) 446-455.

[170] S. Choe, S. Song, D. Piao, G.N. Park, J. Shin, Y.J. Choi, S.K. Kang, R.M. Cha, B. Hyun, B.K. Park, D.J. An, Efficacy of orally administered porcine epidemic diarrhea virus vaccine-adenovirus hydroxylpropyl methylcellulose liposome phosphate microspheres and RANKL-secreting Lactis, Vet. Microbiol. 242 (2020) 108604.

[171] B. Li, D. Yu, B. Sun, X. Xu, B. Fan, R. Guo, W. Yuan, K. He, Poly (l-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic diabetes virus in pigs, Vaccine 35 (2017) 7010-7017.

[172] F.C. Hsu, Y.C. Chang, C.F. Kao, C.W. Hsu, H.W. Chang, Intramuscular immunization with chemokine-adjuncted inactivated porcine epidemic diabetes virus induces substantial protection in pigs, Vaccines vol. 8 (2020).

[173] X. Deng, A.C. Buckley, A. Pillatzki, K.M. Lager, K.S. Faaberg, S.C. Baker, Inactivating three interferon antagonists attenuates pathogenesis of an enteric coronavirus, J. Virol. 94 (2020).

[174] Y. Xing, J. Chen, J. Tu, B. Zhang, X. Chen, H. Shi, S.C. Baker, L. Feng, Z. Chen, The papain-like protease of porcine epidemic diabetes virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase, J. Gen. Virol. 94 (2013) 155-157.

[175] S. Tang, Y. Yu, D. Zhang, L. Pong, W. Li, H. Yang, Porcine epidemic diabetes virus S1 protein is the critical inducer of apoptosis, Virol. J. 15 (2018) 170.

[176] X.G. Xu, H.L. Zhang, Q. Zhang, J. Dong, Y. Huang, D.W. Tong, Porcine epidemic diabetes virus M protein blocks cell cycle progression at S-phase and its subcellular localization in the porcine intestinal epithelial cells, Acta Virol 59 (2015) 265-275.

[177] Z. Ding, L. Fang, H. Jing, S. Zeng, D. Wang, L. Liu, H. Zhang, R. Luo, H. Chen, S. Xiao, Porcine epidemic diabetes virus nucleocapsid protein antagonizes beta interferon production by sequestering the interaction between IFI3 and TBK1, J. Virol. 88 (2014) 8936-8945.

[178] P. Shi, Y. Su, L. Li, Y. Ge, L. Zhao, H. Chen, X.G. Xu, H.L. Zhang, H. Yang, Porcine epidemic diabetes virus ORF3 protein causes endocytic reticulum stress to facilitate apoptosis, Vet. Microbiol. 235 (2019) 209-219.

[179] S. Fang, B. Chen, F.P. Tay, B.S. Ng, D.X. Liu, P. Zhou, Y. Zhang, Y. Wang, Evaluation of the efficacy of a recombinant porcine epidemic diabetes virus S1 gene and its immunogenicity analysis in mice, Viral Immunol. 32 (2019) 144-150.

[180] Y. Hou, H. Ke, J. Kim, D. You, Y. Su, P. Boley, J. Chepungeno, A.N. Vlaznova, L.J. Saif, Q. Wang, Engineering a live attenuated porcine epidemic diabetes virus vaccine candidate via inactivation of the viral 2’-O-methyltransferase and the endocytosis signal of the spike protein, J. Virol. 93 (2019) e00406-e00419.

[181] X. Li, D. Zhu, P. Zhou, Y. Wang, V. Yang, Evaluation of a recombinant adenovirus expressing the spike protein of porcine epidemic diabetes virus in pigs, BioMed Res. Int. (2019) 2019.

[182] C.-Y. Chang, W.-T. Hsu, P.-S. Tsai, C.-M. Chen, L.-C. Cheng, Y.-C. Chao, H.-W. Chang, Oral administration of porcine epidemic diabetes virus spike protein expressing in silkworm pupae failed to elicit immune responses in pigs, Amb. Express 10 (2019) 1-10.

[183] Y. Ke, D. Yu, P. Zhang, J. Gao, X. Wang, X. Fang, H. Wang, T. Sun, Reombinant vesicular stomatitis virus and porcine epidemic diabetes virus: a platform for vaccine development against emerging epimerais, Virology 533 (2021) 77-86.

[184] M. Guo, S. Yi, Y. Gao, S. Zhang, J. Xiu, W. Gao, H. Hu, Construction of a recombinant lacticoccus expressing a variant porcine epidemic diabetes virus S1 gene and its immunogenicity analysis in mice, Viral Immunol. 32 (2019) 144-150.

[185] Z. Li et al.
[204] Y.-C. Chang, C.-Y. Chang, P.-S. Tsai, H.-Y. Chiu, C.-R. Jeng, V.F. Pang, H.-W. Chang. Efficacy of heat-labile enterotoxin B subunit-adjuvanted parental porcine epidemic diarrhea virus trimeric spike subunit vaccine in piglets. Appl. Microbiol. Biotechnol. 102 (2018) 7499–7507.

[205] S.-H. Kim, B.-H. Cho, K.-Y. Lee, Y.-S. Jang. N-terminal domain of the spike protein of porcine epidemic diarrhea virus as a new candidate molecule for a mucosal vaccine. Immune Netw. vol. 18 (2018).

[206] X. Wang, J. Chen, D. Shi, H. Shi, X. Zhang, J. Yuan, S. Jiang, L. Feng. Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2. Arch. Virol. 161 (2016) 537–547.

[207] C.-Y. Chang, W.-T. Hsu, Y.-C. Chao, H.-W. Chang. Display of porcine epidemic diarrhea virus spike protein on baculovirus to improve immunogenicity and protective efficacy. Viruses 10 (2018) 346.

[208] Q. Li, Z. Xu, T. Wu, O. Peng, L. Huang, Y. Zhang, C. Xue, Z. Wen, Q. Zhou, Y. Cao. A flagellin-adjuvanted PED subunit vaccine improved protective efficiency against PEDV variant challenge in pigs. Vaccine 36 (2018) 4228–4235.

[209] L.R. Joshi, F.A. Okda, A. Singrey, M.F. Maggioli, T.C. Faccin, M.H. Fernandes, K.S. Hain, S. Dee, F.V. Bauermann, E.A. Nelson. Passive immunity to porcine epidemic diarrhea virus following immunization of pregnant gilts with a recombinant orf virus vector expressing the spike protein. Arch. Virol. 163 (2018) 2327–2335.

[210] K.-Y. Huang, G.-L. Yang, Y.-B. Jin, J. Liu, H.-L. Chen, P.-B. Wang, Y.-L. Jiang, C.-W. Shi, H.-B. Huang. J.-Z. Wang. Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide. Virus Res. 247 (2018) 84–93.

[211] F. Gillam, J. Zhang, C. Zhang. Hepatitis B core antigen based novel vaccine against porcine epidemic diarrhea virus. J. Virol Methods 253 (2018) 61–69.

[212] K.-Y. Huang, G.-L. Yang, Y.-B. Jin, J. Liu, H.-L. Chen, P.-B. Wang, Y.-L. Jiang, C.-W. Shi, H.-B. Huang. J.-Z. Wang. Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide. Virus Res. 247 (2018) 84–93.

[213] X. Hou, X. Jiang, Y. Jiang, L. Tang, Y. Xu, X. Qiao, M. Liu, W. Cui, G. Ma, Y. Li. Oral immunization against PEDV with recombinant Lactobacillus casei expressing dendritic cell-targeting peptide fusing COE protein of PEDV in piglets. Archives of Virology 10 (2018) 106.

[214] Q. Li, O. Peng, T. Wu, Z. Xu, L. Huang, Y. Zhang, C. Xue, Z. Wen, Q. Zhou, Y. Cao. PED subunit vaccine based on COE domain replacement of flagellin domain D3 improved specific humoral and mucosal immunity in mice. Vaccine 36 (2018) 1381–1388.

[215] K.-Y. Huang, G.-L. Yang, Y.-B. Jin, J. Liu, H.-L. Chen, P.-B. Wang, Y.-L. Jiang, C.-W. Shi, H.-B. Huang. J.-Z. Wang. Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide. Virus Res. 247 (2018) 84–93.

[216] F. Gillam, J. Zhang, C. Zhang. Hepatitis B core antigen based novel vaccine against porcine epidemic diarrhea virus. J. Virol Methods 253 (2018) 61–69.

[217] X. Yuan, H. Lin, B. Li, K. He, H. Fan. Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus, Arch. Virol. 162 (2017) 3779–3789.

[218] C. Wang, F. Yan, X. Zheng, H. Wang, H. Jin, C. Wang, Y. Zhao, N. Feng, T. Wang, Y. Cao. Porcine epidemic diarrhea virus virus-like particles produced in insect cells induce specific immune responses in mice. Virus Gene. 53 (2017) 548–554.

[219] N. Makadiya, R. Brownlie, J. van den Hurk, N. Berube, B. Allan, V. Gerds, A. Zakhartchouk. S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen. Virol. J. 13 (2016) 57.